Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/IAE.0000000000002334 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Fingolimod-Associated Macular Edema in the Treatment of Multiple Sclerosis.
Cureus
July 2023
Internal Medicine/Family Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Multiple sclerosis is a neurological disorder categorized by inflammatory processes with a high prevalence worldwide. It affects both motor and sensory pathways and is also associated with the visual pathway. Fingolimod is a commonly used drug for relapsing-remitting multiple sclerosis.
View Article and Find Full Text PDFSiponimod-related bilateral cystoid macular oedema and intravenous fluorescein angiographic findings in a patient with stable proliferative diabetic retinopathy without history of diabetic macular oedema.
BMJ Case Rep
November 2022
Ophthalmology, The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA.
Siponimod is a sphingosine-1-phosphate receptor modulator used as disease-modifying therapy for relapsing-remitting multiple sclerosis similar to Fingolimod which has been known to cause dose dependent fingolimod associated macular oedema (FAME). We report a case of delayed onset bilateral cystoid macular oedema in a patient with stable proliferative diabetic retinopathy who developed cystoid macular oedema in the setting of siponimod (Mayzent; Novartis Pharmaceuticals; Cambridge, Massachusetts, USA) use. As with FAME, cystoid macular oedema resolved in the patient's eyes with drug cessation and adjunctive topical anti-inflammatory therapy.
View Article and Find Full Text PDFFingolimod-associated central serous chorioretinopathy in a young girl.
BMJ Case Rep
August 2021
Ophthalmology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, Tamil Nadu, India
Fingolimod is a sphingosine-1-phosphate analogue used for the treatment of multiple sclerosis. We, hereby, report a rare case of fingolimod-associated central serous chorioretinopathy (CSCR) in a 21-year-old woman who presented with blurring of vision in the right eye 3 weeks after initiation of oral fingolimod. On examination, best-corrected visual acuity was 20/20 in both the eyes.
View Article and Find Full Text PDFBilateral fingolimod-associated macular oedema development after cataract surgery.
BMJ Case Rep
June 2021
Department of Ophthalmology, Imperial College Healthcare NHS Trust, London, UK
Postoperative cystoid macular oedema (CMO) is a recognised complication of cataract surgery, occurring in around 1.5% of cases. It is generally managed with topical steroids or non-steroidal anti-inflammatory medications.
View Article and Find Full Text PDFFingolimod-associated macular edema: A case report of late onset.
Eur J Ophthalmol
July 2022
General Hospital of Athens Korgialenio Benakio, Athens, Attica, Greece.
Introduction: The authors present a case of a male with Multiple Sclerosis (MS) who developed unilateral Fingolimod-Associated Macular Edema (FAME) 10 years after initiating fingolimod therapy. By reporting this case study, the authors present a comprehensive review on FAME, its current incidence, and therapy options in MS patients.
Case Description: A 58-year-old Caucasian male patient was referred to the hospital with a history of MS.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!